Sickle-cell disease: long-term care

01Purpose and principlesWhat the treatment does and how it fits into care.

Deoxygenated haemoglobin S polymerises, deforming erythrocytes and promoting haemolysis, endothelial adhesion, inflammation and microvascular obstruction. Repeated episodes cause cumulative organ damage even between recognised crises. Baseline haemoglobin, haemolysis and pain burden vary by genotype and modifiers such as fetal haemoglobin, alpha-thalassaemia coinheritance and renal function. A personal baseline therefore matters when interpreting acute change, but it must never be used to normalise new hypoxia, fever or neurological deficit.

A structured annual review turns silent damage into actionable findings. Measure blood pressure accurately; check renal function and urine albumin because hyperfiltration can precede falling eGFR. Review dyspnoea, resting or nocturnal hypoxia, exercise change and sleep-disordered breathing rather than ordering screening echocardiography without a clinical question. Arrange retinal assessment under local specialist policy and examine persistent bone or joint pain for avascular necrosis. Review vaccination, antibiotic supply, dental health and travel, including malaria prevention where relevant.

Disease modification is broader than analgesia. Hydroxycarbamide reduces vaso-occlusive events and acute chest syndrome and may improve survival, but requires informed consent, contraception or pregnancy planning and full-count titration. Chronic transfusion is used for defined indications such as stroke prevention, not simply low steady-state haemoglobin. Stem-cell transplantation or newer commissioned therapies are considered in specialist centres. Education should cover hydration without excess, temperature extremes, graded activity, smoking avoidance and prompt help, while avoiding blame for unpredictable biological events.

Key points

Sickle-cell disease is a lifelong multisystem disorder; absence of recent pain admissions does not exclude progressive renal, pulmonary, neurological, retinal or skeletal injury.
Every patient should have named specialist follow-up, an individual acute-pain plan, primary-care coordination and a record of genotype, baseline haemoglobin and transfusion antibodies.
Hydroxycarbamide increases fetal haemoglobin and reduces painful crises and acute chest syndrome; offer it through shared specialist discussion when benefits fit the clinical phenotype.
Daily adherence, blood-count monitoring and reproductive counselling determine hydroxycarbamide safety and effectiveness more than prescribing the medicine once.
Functional hyposplenism develops early, so vaccination, antimicrobial prophylaxis where indicated and immediate assessment of fever remain central across adulthood.
Children require transcranial Doppler surveillance through the national pathway to identify high stroke risk and trigger preventive transfusion decisions.
Annual review should address blood pressure, urinalysis or albuminuria, kidney and liver function, vision, oxygenation, gallstones, hip or shoulder pain and cardiopulmonary symptoms.
Ask directly about priapism, menstrual health, contraception, pregnancy plans, fertility, sexual function, sleep, mood, school or work and opioid burden.
Avoid routine iron unless deficiency is demonstrated; chronic transfusion can cause iron overload and alloimmunisation even when baseline anaemia is substantial.
Curative allogeneic transplantation and gene-based therapies are specialist options for selected patients; eligibility, long-term uncertainty and equity of access require early referral rather than promises.

02Indications, selection and cautionsWho may benefit, who needs urgent treatment and important alternatives.

Silent renal injury

Albuminuria or hyperfiltration may emerge before creatinine rises, so normal routine renal indices do not exclude early sickle nephropathy.

Avascular necrosis

Persistent deep hip or shoulder pain, limited rotation and functional decline differ from a short generalised pain episode and need imaging.

Proliferative retinopathy

Visual floaters, field loss or sudden reduced vision may reflect retinal vascular complications and requires urgent ophthalmic assessment.

Acute organ warningRed flag

New hypoxia, focal neurology, sustained priapism or fever exceeds routine long-term review and activates emergency care.

Treatment burden

Missed appointments, escalating opioid use or absent monitoring may reflect access, adverse effects, stigma or mental distress rather than simple non-adherence.

03Assessment before treatmentTests and checks that guide safe selection.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
Full count and reticulocytesFirst step
Why
Establish steady-state anaemia, marrow response and treatment toxicity.
Interpretation and limitations
Compare with personal baseline; falling neutrophils or platelets may limit hydroxycarbamide, while reticulocytopenia during anaemia suggests aplasia or suppression.
02
Renal profile and urine albumin-creatinine ratio
Why
Detect hyperfiltration, albuminuria and declining kidney function.
Interpretation and limitations
Creatinine can underestimate impairment because of low muscle mass and hyperfiltration; persistent albuminuria merits nephrology and disease-specific review.
03
Liver profile and iron assessment
Why
Distinguish haemolysis, hepatobiliary disease and transfusional iron loading.
Interpretation and limitations
Baseline bilirubin may be raised, but cholestatic change or synthetic dysfunction is not routine haemolysis; ferritin trends require inflammation and transfusion context.
04
Transcranial Doppler in children
Why
Measure cerebral arterial velocity for primary stroke-risk stratification.
Interpretation and limitations
Abnormal velocity is confirmed and managed through the national sickle pathway, commonly with a long-term transfusion programme rather than isolated aspirin.
05
Ophthalmic examination
Why
Identify peripheral sickle retinopathy before or after visual symptoms.
Interpretation and limitations
Specialist retinal findings determine observation, laser or other treatment; urgent new visual loss bypasses routine surveillance.
06
Symptom-directed cardiopulmonary testing
Why
Investigate dyspnoea, hypoxia, reduced exercise or sleep symptoms.
Interpretation and limitations
Pulse oximetry, imaging, lung function, sleep study or echocardiography follows the phenotype; one estimated pulmonary pressure does not establish pulmonary hypertension.
07
Red-cell antibody and genotype record
Why
Preserve safe transfusion information across organisations.
Interpretation and limitations
Historical antibodies remain clinically relevant even when currently undetectable and must accompany future compatibility requests.

04Treatment approachPreparation, options, escalation and aftercare.

01Annual reviewSearch for quiet organ injuryFirst stepA person with sickle-cell disease attends scheduled specialist follow-up.

1Reconcile genotype, baseline haematology, admissions, transfusions, antibodies, medicines, vaccines and the individual emergency plan with patient-held information.
2Assess renal, hepatic, cardiopulmonary, neurological, retinal, musculoskeletal, sexual and mental-health domains using age-appropriate tests and symptom triggers.
3Agree a small set of actions, responsible teams and review dates, sharing the plan with primary care, emergency services and maternity or other specialties when relevant.

02Disease modificationMatch therapy to burden and goalPain, acute chest syndrome, anaemia or organ risk remains clinically important.

1Discuss hydroxycarbamide benefits, uncertainties, monitoring, contraception and adherence and document the outcome even when the patient reasonably declines.
2Use transfusion only for a defined indication with antigen matching and iron planning, and refer severe phenotypes early for transplant or advanced-therapy assessment.
3Measure benefit through acute events, hospital use, function, organ trajectory and adverse effects, revising treatment collaboratively rather than judging success by MCV alone.

03Life-stage carePlan transitions before risk peaksAdolescence, pregnancy planning, surgery, travel or a change in independence approaches.

1Begin paediatric-to-adult transition with joint visits, medicine knowledge, emergency navigation and consent skills rather than a single administrative handover.
2Refer preconceptionally to specialist haemoglobinopathy and obstetric teams, reviewing hydroxycarbamide, transfusion history, alloantibodies and partner carrier status.
3For surgery or travel create a written plan covering oxygenation, hydration, thrombosis, analgesia, transfusion, vaccines, prophylaxis and access to urgent care.

05Regimens, contraindications and interactionsTreatment details and the circumstances that modify them.

Raises fetal haemoglobin and reduces vaso-occlusive pain, acute chest syndrome and transfusion need in appropriately selected sickle-cell disease.

Hydroxycarbamide

Specialists commonly begin at 15 mg/kg orally once daily, reduce the starting dose in renal impairment and titrate in small steps against counts, tolerance and clinical response to a maximum tolerated dose, usually not exceeding 35 mg/kg/day.

Myelosuppression requires regular counts and protocol dose holds; discuss pregnancy, contraception, fertility, skin and nail effects and avoid live vaccines or interacting cytotoxic treatment without review.

Reduces invasive pneumococcal disease risk as one layer alongside vaccination and urgent fever treatment.

Phenoxymethylpenicillin prophylaxis

Use the current age- and risk-based sickle or asplenia protocol, commonly 250 mg orally twice daily in adults when ongoing prophylaxis is indicated, with an allergy alternative.

Missed doses, resistant organisms and non-pneumococcal pathogens remain possible; never let prophylaxis delay emergency assessment and parenteral antibiotics for systemic illness.

Supports increased erythropoiesis where folate demand exceeds intake but does not modify sickling biology.

Folic acid

Prescribe under the haemoglobinopathy service when dietary intake, pregnancy or sustained haemolytic demand warrants it, commonly 5 mg orally once daily in UK practice.

Assess vitamin B12 where relevant and avoid presenting supplementation as an alternative to hydroxycarbamide, transfusion or organ surveillance.

06Complications, monitoring and follow-upAdverse effects, response and longer-term review.

During hydroxycarbamide follow full count, reticulocytes, renal and liver function at protocol intervals and after every significant dose change.
Record painful events, acute chest episodes, hospital days and home recovery alongside school, work, sleep and physical function.
At least annually review blood pressure, urine albumin, renal and liver indices, oxygenation symptoms, vision, joint symptoms and transfusion iron burden.
Reconcile vaccination and antimicrobial prevention with primary care and repeat fever education, especially after transition or travel.
Review opioids for benefit, sedation, constipation, tolerance, dependence and accidental overdose while preserving timely analgesia for genuine acute pain.
Document fertility, contraception and pregnancy intentions repeatedly because circumstances and disease-modifying treatment choices change over time.

07Special situationsVariants, exceptions and circumstances that change the usual approach.

Baseline is a comparator

Personal haemoglobin and oxygenation help interpret change but never make a new dangerous deviation automatically benign.

MCV is not the outcome

Macrocytosis can support hydroxycarbamide exposure, yet clinical events, organ health and patient function define meaningful benefit.

Creatinine can reassure falsely

Hyperfiltration and low muscle mass may keep creatinine deceptively low while albuminuria and nephron injury are developing.

Transition is clinical risk

Loss of continuity, prescriptions and emergency familiarity during transfer to adult services can increase preventable acute harm.

08Common pitfallsFrequent interpretation and management errors.

01
Measuring success only by emergency admission count.
02
Prescribing iron without demonstrating deficiency.
03
Using hydroxycarbamide without count or reproductive review.
04
Ignoring historical red-cell antibodies after they disappear serologically.
05
Treating transition as a referral letter rather than a process.
06
Assuming a quiet pain year means no organ progression.